-
Product Insights
NewElectrophysiology Ablation Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Electrophysiology Ablation Catheters Pipeline Market Report Overview Electrophysiology ablation is applicable for a wide variety of arrhythmias and has an extremely high success rate with low rates of complication and recurrence. The electrophysiology ablation catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and...
-
Product Insights
NewBreast Implants Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Breast Implants Pipeline Market Report Overview Breast Implants are also known as intensive-care ventilators. They provide artificial respiratory support to critical patients in ICUs. The Breast Implants pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments...
-
Sector Analysis
NewDigital Oilfield Market Size, Share, Trends, and Analysis by Product, End-Use, Region and Segment Forecast to 2030
Accessing the in-depth insights from the ‘Digital Oilfield’ report can help: In evaluating market size based on product, end-use, and regional markets Detailed mapping of the entire value chain and its associated stages Country-level insights with breakdown provided for key market segments Potential revenue growth opportunities in product and end-use segments supported by concise qualitative commentary Foresee possible changing dynamics of the sector and align business strategies to capitalize on them List of key upcoming projects and company market ranking...
-
Sector Analysis
NewHungary Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Hungary Defense Market Report Overview In 2024, Hungary's defense budget is worth $4.6 billion. The country’s defense budget will grow at a CAGR of more than 6% during 2025-2029. The largest component of Hungary’s defense expenditure every year is acquisition. This is the result of the ongoing ZrÃnyi Modernization Program to update Hungary’s aging military equipment, much of which is still a holdover from the Soviet era. Hungary Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for More...
-
Product Insights
NewNet Present Value Model: Erasca Inc’s ERAS-007
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-007 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1008 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1008 in Triple-Negative Breast Cancer (TNBC) Drug Details: CBP-1008 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Macitentan in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Macitentan in Pulmonary Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macitentan in Pulmonary Hypertension Drug Details: Macitentan (Opsumit, Zependo) is a novel...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Secukinumab in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Secukinumab in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secukinumab in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Secukinumab in Polymyalgia Rheumatica (PMR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Secukinumab in Polymyalgia Rheumatica (PMR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secukinumab in Polymyalgia Rheumatica (PMR) Drug Details: Secukinumab (Cosentyx, Zafrez,...